SavedAdd your journal

Journals / Güncel Retina Dergisi / 2017 / Cilt: 1 - Sayı: 3

Intravitreal Bevacizumab Treatment in Wet-Form (Neovascular) Age-Related Macular Degeneration

Yaş Tip (Neovasküler) Yaşa Bağlı Makula Dejenerasyonunda İntravitreal Bevacizumab Tedavisi

Burak ERDEN
Selim BÖLÜKBAŞI
MUSTAFA NURİ ELÇİOĞLU
Pages
206–212
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This article mentions about the standpoint of the offlabel used anti-VEGF, bevacizumab, according to the literature

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Age-related macular dejeneration is one of the main causes of visual loss in older population.
📊
Key Findings & Data:In recent years, agents developed to aim the inhibition of the vascular endothelial growth factor are the main choise for the treatment of choroidal neovascular membranes often found in the wet type of this disease.
💡
Conclusion & Impact:This article mentions about the standpoint of the offlabel used anti-VEGF, bevacizumab, according to the literature
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Age-related macular dejeneration is one of the main causes of visual loss in older population. In recent years, agents developed to aim the inhibition of the vascular endothelial growth factor are the main choise for the treatment of choroidal neovascular membranes often found in the wet type of this disease. This article mentions about the standpoint of the offlabel used anti-VEGF, bevacizumab, according to the literature

Özet

Yaşa bağlı makula dejenerasyonu toplumda ileri yaşta görme kaybının önemli bir nedenidir. Hastalığın yaş tipinde görülen koroidal neovasküler membranların tedavisinde son yıllarda vasküler endotelyal growth (VEGF) faktör inhibisyonu amacıyla geliştirilen ajanlar tedavinin temelini oluşturmaktadır. Bu yazıda anti-VEGF ajanlar içinde off-label kullanılmak durumunda olan bevacizumab ile ilgili literatürdeki durumdan bahsedilecektir

🔖

Cite This Article

ERDEN, B., BÖLÜKBAŞI, S., ELÇİOĞLU, M. N. (2017). Intravitreal Bevacizumab Treatment in Wet-Form (Neovascular) Age-Related Macular Degeneration. Güncel Retina Dergisi, Cilt: 1 - Sayı: 3, 206–212. https://ajindex.com/articles/216209

References (1)

  1. Bressler NM, Bressler SB, Congdon NG, Ferris FLr, Friedman DS, Klein R, Lindblad AS, Milton RC, Seddon JM, Age-Related Eye Disease Study Research Group Potential public health impact of age-related eye disease study results: AREDS report no. 11. Arch Ophthalmol 2003;121:1621–1624 2. Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J et al. The burden of age-related macular degeneration:a value based analysis. Curr Opin Ophthalmol 2006;17:257–266 3. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640–2. 4. Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001;119:198–207 5. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic factors in age-related maculopathy. Br J Ophthalmol 1997;81:154–162. 6. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 30;351(27):2805-16. 7. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-31. 8. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1432-44. 9. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups.Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec;119(12):2537-48 10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. 11. Seo MS, Kwak N, Ozaki H, Yamada H, Okamoto N, Yamada E, Fabbro D, Hofmann F, Wood JM, Campochiaro PA. Dramatic inhibition of retinal and choro